Clinical trials
Advanced Lung Cancer clinical trials
Below are recruiting advanced lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,308 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07744698RecruitingPhase 4
Maintenance therapy for advanced lung cancer
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
Hefei, AnhuiAges 18–75 - NCT04181060RecruitingPhase 3
Osimertinib alone or with bevacizumab for EGFR-mutant lung cancer
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
Anchorage, AlaskaAges 18 years+ - NCT03191149RecruitingPhase 2
Osimertinib for lung cancer with an EGFR exon 20 change
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
Anchorage, AlaskaAges 18 years+ - NCT07742332RecruitingPhase 2
Targeted therapy before surgery for EGFR-mutant lung cancer
This trial tests a combination of two targeted medicines (befotertinib and bevacizumab) before surgery for people with EGFR-mutant non-small cell lung cancer that cannot be removed right away. The goal is to see if this treatment can shrink the tumor and improve surgery outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07185997RecruitingPhase 3
Testing firmonertinib for a type of lung cancer with rare EGFR mutations
This trial tests a new drug, firmonertinib, against other EGFR inhibitors as a first treatment for advanced lung cancer that has specific rare EGFR mutations (PACC mutations). It is for people who haven't had other treatments for their advanced cancer.
Fullerton, CaliforniaAges 18 years+ - NCT07489066RecruitingPhase 2
Study of PF-08634404 for early-stage or locally advanced lung cancer
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
Huntsville, AlabamaAges 18 years+ - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Miami, FloridaAges 18 years+ - NCT07623356RecruitingPhase 1/Phase 2
Study of AK138D1 alone or with ivonescimab for advanced lung cancer
This trial tests an experimental drug called AK138D1, either by itself or combined with another drug (ivonescimab), for people with advanced non-small cell lung cancer that has spread. It aims to see if these treatments are safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07017829RecruitingPhase 2
GT103 plus pembrolizumab for STK11 mutant lung cancer
This trial tests a new drug called GT103 combined with the immunotherapy pembrolizumab (Keytruda) for people with advanced lung cancer that has a specific genetic change (STK11 mutation) and has continued to grow despite prior pembrolizumab treatment. The goal is to see if adding GT103 can help shrink tumors or slow the cancer's growth.
Buffalo, New YorkAges 18 years+ - NCT07321106RecruitingPhase 1
CBI-1214 for advanced colorectal cancer
This trial tests a new drug called CBI-1214, which is designed to help your immune system attack cancer cells. It is for people with advanced colorectal cancer that has not responded to other treatments.
Phoenix, ArizonaAges 18 years+ - NCT07339059RecruitingPhase 2
Maintenance therapy for advanced small cell lung cancer
This trial tests two immunotherapy drugs (sacituzumab govitecan with atezolizumab or durvalumab) as ongoing treatment to keep extensive-stage small cell lung cancer from progressing. It is for people who have already completed initial chemotherapy and immunotherapy without their cancer getting worse.
Detroit, MichiganAges 18 years+ - NCT06910657RecruitingPhase 1
IDOV-Immune vaccine for advanced solid tumors
This trial tests an experimental virus-based treatment for people with advanced solid tumors that have stopped responding to standard therapies. The treatment is designed to infect and destroy cancer cells while boosting the immune system.
St Louis, MissouriAges 18 years+ - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
Athens, GeorgiaAges 18 years+ - NCT07632365RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for inoperable stage III lung cancer
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
Shanghai, XuhuiAges 18 years+ - NCT05142189RecruitingPhase 1
Testing BNT116 for advanced non-small cell lung cancer
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Lexington, KentuckyAges 18 years+ - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Duarte, CaliforniaAges 18 years+ - NCT07222566RecruitingPhase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Bullhead City, ArizonaAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Birmingham, AlabamaAges 18–130 - NCT07227298RecruitingPhase 1/Phase 2
Study of new drug combo for advanced lung cancer
This study tests a new combination of cancer drugs (PF-08634404 with other anticancer agents) for people with advanced non-small cell lung cancer who have not yet received any treatment for their advanced disease. It aims to see if this combination can shrink tumors or slow cancer growth.
Fayetteville, ArkansasAges 18 years+ - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT07472517RecruitingPhase 3
Comparing a new drug combo for advanced small cell lung cancer
This trial tests a new investigational drug called obrixtamig combined with standard chemotherapy (atezolizumab, carboplatin, etoposide) for people with advanced small cell lung cancer that has spread. It aims to see if this new combination works better than the standard treatment alone.
Mobile, AlabamaAges 18 years+ - NCT07253142RecruitingPhase 2
Study of HLX43 with Serplulimab for advanced lung cancer
This trial tests a new combination of two drugs for people with advanced lung cancer that has worsened after previous treatments like chemotherapy or immunotherapy. The goal is to see if this approach can help shrink tumors or slow the disease.
Hefei, AnhuiAges 18–75 - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT06096844RecruitingPhase 3
Chemo plus immunotherapy vs immunotherapy alone for older adults with advanced lung cancer
This trial compares chemotherapy combined with immunotherapy to immunotherapy alone for adults 70 and older with advanced non-small cell lung cancer that has a specific protein level (PD-L1 1-49%). It aims to find which treatment works better for this group.
Fayetteville, ArkansasAges 70 years+
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced lung cancer?
- Yes. Clin2 currently lists 1,308 recruiting advanced lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- EGFR Mutant Advanced Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.